ATE319996T1 - Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin - Google Patents

Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Info

Publication number
ATE319996T1
ATE319996T1 AT00981763T AT00981763T ATE319996T1 AT E319996 T1 ATE319996 T1 AT E319996T1 AT 00981763 T AT00981763 T AT 00981763T AT 00981763 T AT00981763 T AT 00981763T AT E319996 T1 ATE319996 T1 AT E319996T1
Authority
AT
Austria
Prior art keywords
mortalin
cure
finding
cancer
interaction domain
Prior art date
Application number
AT00981763T
Other languages
English (en)
Inventor
Renu Chugai Wadhwa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE319996T1 publication Critical patent/ATE319996T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00981763T 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin ATE319996T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35754599 1999-12-16

Publications (1)

Publication Number Publication Date
ATE319996T1 true ATE319996T1 (de) 2006-03-15

Family

ID=18454687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981763T ATE319996T1 (de) 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Country Status (6)

Country Link
US (1) US20030087263A1 (de)
EP (1) EP1243923B1 (de)
AT (1) ATE319996T1 (de)
AU (1) AU1891801A (de)
DE (1) DE60026576T2 (de)
WO (1) WO2001044807A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295976A1 (de) 2003-03-08 2011-03-16 Auvation Ltd Marker für Darmkrebs
EP1536230A1 (de) * 2003-11-28 2005-06-01 Deutsches Rheuma-Forschungszentrum Berlin Durchflusszytometrischer Partikel-basierter Bindungsassay
JP2006089471A (ja) 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2906954B1 (de) * 2012-10-09 2018-04-11 Ramot at Tel-Aviv University Ltd. Verfahren und kits zur prognose von krebs unter verwendung von löslichem mortalin im blut
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023555A1 (fr) * 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Prolongation de la duree de vie d'une cellule normale
GB2379447B (en) * 2000-05-17 2004-12-29 Geron Corp Neural progenitor cell populations
JP2001354564A (ja) * 2000-06-14 2001-12-25 Chugai Bunshi Igaku Kenkyusho:Kk カチオン性ローダシアニン系色素誘導体を有効成分とする、ｍｏｔ−２蛋白質とｐ５３蛋白質の相互作用阻害剤

Also Published As

Publication number Publication date
DE60026576D1 (de) 2006-05-04
EP1243923A4 (de) 2004-05-06
AU1891801A (en) 2001-06-25
US20030087263A1 (en) 2003-05-08
WO2001044807A1 (fr) 2001-06-21
EP1243923B1 (de) 2006-03-08
EP1243923A1 (de) 2002-09-25
DE60026576T2 (de) 2007-01-18

Similar Documents

Publication Publication Date Title
ATE319996T1 (de) Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin
EP2267018A3 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
CY1110549T1 (el) Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
ATE540319T1 (de) Verfahren für die bestimmung von fk506
ATE343788T1 (de) Verfahren zum simultanen nachweis von beiden gliedern eines bindungspaares
DE60137356D1 (de) Erweiterter "tethering" ansatz zum schnellen auffinden von liganden
WO2020198264A8 (en) Modified cleavases, uses thereof and related kits
WO2003011898A3 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
DE60318744D1 (de) ZUSAMMENSETZUNG AUF BASIS VON 2-CYANOACRYLAT, VERFAHREN UND MITTEL ZUR EVALUIERUNG DER HuRTUNG DAVON
DK1705183T3 (da) Bindingsmolekyler for human faktor VIII og faktor VIII-lignende proteiner
DE58901562D1 (de) Verfahren zur koagulation von lacken und anderen organischen beschichtungen.
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
WO2003002724A3 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
DE1105508T1 (de) Verfahren zur reinigung von proteinen und biomolekül- oder proteinkomplexen
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE60206173D1 (de) Härtende zusammensetzung und verfahren zum aufbringen von alkydbeschichtungsmaterial damit
DE69924120D1 (de) Für ataxin-2-bindende proteine kodierende nukleinsäure, damit verwandten produkten und verfahren zur deren anwendung
ATE284034T1 (de) Verfahren zum nachweis von protein s
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
DE69922245D1 (de) Biologisch wirksame konjugate mit einem reporterrest und verfahren zu dessen nachweis
DE59702207D1 (de) Verfahren zur eignungsprüfung von faktor viii-haltigen proteinfraktionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties